{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:01:56Z","timestamp":1790402516134,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T00:00:00Z","timestamp":1707177600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007642","name":"Universit\u00e0 degli Studi di Roma Tor Vergata","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007642","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lung"],"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>This study aimed to examine reports of cardiovascular adverse events (CV AEs) observed in the real-world during treatment with aclidinium, tiotropium, glycopyrronium, and umeclidinium alone or in combination with a LABA and, in the context of triple therapy, with the addition of an ICS, and submitted to the food and drug administration adverse event reporting system (FAERS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective disproportionality analysis was conducted utilizing CV AE reports submitted to the FAERS from January 2020 to 30 September 2023. Disproportionality was measured by calculating the reporting odds ratio.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with ipratropium, tiotropium was associated with fewer reports of CV AEs. Compared with tiotropium, other LAMAs were more likely to be associated with reports of CV AEs. Combinations of glycopyrronium with indacaterol or formoterol and umeclidinium with vilanterol significantly reduced reports of CV AEs compared with the respective LAMA. The addition of an ICS to these combinations further reduced the risk of CV AE reports.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our study suggests that inhaled LAMAs are not free from cardiac AE risks. This risk may be more evident when the newer LAMAs are used, but it is generally significantly reduced when COPD patients are treated with dual bronchodilators or triple therapy. However, these results do not prove that LAMAs cause CV AEs, as FAERS data alone are not indicative of a drug\u2019s safety profile. Given the frequency with which COPD and cardiovascular disease co-exist, a large study in the general population could shed light on this very important issue.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00408-024-00677-3","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T18:09:15Z","timestamp":1707242955000},"page":"119-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020\u20132023"],"prefix":"10.1007","volume":"202","author":[{"given":"Maria Gabriella","family":"Matera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigino","family":"Calzetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Hanania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Cazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,6]]},"reference":[{"issue":"1","key":"677_CR1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s41030-021-00179-0","volume":"8","author":"CI Bloom","year":"2022","unstructured":"Bloom CI, Montonen J, J\u00f6ns O, Garry EM, Bhatt SP (2022) First maintenance therapy for chronic obstructive pulmonary disease: retrospective analyses of US and UK healthcare databases. Pulm Ther 8(1):57\u201374. https:\/\/doi.org\/10.1007\/s41030-021-00179-0","journal-title":"Pulm Ther"},{"issue":"3","key":"677_CR2","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.pupt.2012.12.006","volume":"26","author":"M Cazzola","year":"2013","unstructured":"Cazzola M, Page C, Matera MG (2013) Long-acting muscarinic receptor antagonists for the treatment of respiratory disease. Pulm Pharmacol Ther 26(3):307\u2013317. https:\/\/doi.org\/10.1016\/j.pupt.2012.12.006","journal-title":"Pulm Pharmacol Ther"},{"key":"677_CR3","first-page":"238","volume-title":"Cardiovascular complications of respiratory disorders (ERS monograph)","author":"D Stolz","year":"2020","unstructured":"Stolz D, Cazzola M (2020) Characterising the cardiovascular safety profile of inhaled muscarinic receptor antagonists. In: Mart\u00ednez-Garc\u00eda MA, P\u00e9pin J-L, Cazzola M (eds) Cardiovascular complications of respiratory disorders (ERS monograph). European Respiratory Society, Sheffield, pp 238\u2013250"},{"issue":"13","key":"677_CR4","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1001\/jamainternmed.2013.1016","volume":"173","author":"A Gershon","year":"2013","unstructured":"Gershon A, Croxford R, Calzavara A, To T, Stanbrook MB, Upshur R, Stukel TA (2013) Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med 173(13):1175\u20131185. https:\/\/doi.org\/10.1001\/jamainternmed.2013.1016","journal-title":"JAMA Intern Med"},{"issue":"8","key":"677_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1136\/jim-2021-001931","volume":"69","author":"C Zhang","year":"2021","unstructured":"Zhang C, Zhang M, Wang Y, Xiong H, Huang Q, Shuai T, Liu J (2021) Efficacy and cardiovascular safety of LAMA in patients with COPD: a systematic review and meta-analysis. J Investig Med 69(8):1391\u20131398. https:\/\/doi.org\/10.1136\/jim-2021-001931","journal-title":"J Investig Med"},{"issue":"6","key":"677_CR6","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s40264-016-0402-4","volume":"39","author":"MG Matera","year":"2016","unstructured":"Matera MG, Rogliani P, Calzetta L, Cazzola M (2016) Safety considerations with dual bronchodilator therapy in COPD: an update. Drug Saf 39(6):501\u2013508. https:\/\/doi.org\/10.1007\/s40264-016-0402-4","journal-title":"Drug Saf"},{"issue":"1","key":"677_CR7","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1177\/2042098616667304","volume":"8","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Rogliani P, Matera MG (2017) Tiotropium formulations and safety: a network meta-analysis. Ther Adv Drug Saf 8(1):17\u201330. https:\/\/doi.org\/10.1177\/2042098616667304","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"677_CR8","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1080\/14728214.2020.1758059","volume":"25","author":"MG Matera","year":"2020","unstructured":"Matera MG, Belardo C, Rinaldi M, Rinaldi B, Cazzola M (2020) Emerging muscarinic receptor antagonists for the treatment of asthma. Expert Opin Emerg Drugs 25(2):123\u2013130. https:\/\/doi.org\/10.1080\/14728214.2020.1758059","journal-title":"Expert Opin Emerg Drugs"},{"key":"677_CR9","unstructured":"U.S. Food and Drug Administration (2023) FDA adverse event reporting system (FAERS) public dashboard. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reporting-system-faers-public-dashboard. Accessed 15 Dec 2023"},{"issue":"2","key":"677_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s12325-022-02346-4","volume":"40","author":"SD Silberstein","year":"2023","unstructured":"Silberstein SD, Reshef S, Cohen JM, Gandhi S, Seminerio M, Ramirez Campos V, Kessler Y, Thompson SF, Blumenfeld A (2023) Adverse events reported with therapies targeting the CGRP pathway during the first 6 months post-launch: a retrospective analysis using the FDA adverse events reporting system. Adv Ther 40(2):445\u2013459. https:\/\/doi.org\/10.1007\/s12325-022-02346-4","journal-title":"Adv Ther"},{"issue":"1","key":"677_CR11","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1136\/thoraxjnl-2011-201275","volume":"68","author":"S Singh","year":"2013","unstructured":"Singh S, Loke YK, Enright P, Furberg CD (2013) Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax 68(1):114\u2013116. https:\/\/doi.org\/10.1136\/thoraxjnl-2011-201275","journal-title":"Thorax"},{"issue":"1","key":"677_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pupt.2011.10.004","volume":"25","author":"KM Verhamme","year":"2012","unstructured":"Verhamme KM, Afonso AS, van Noord C, Haag MD, Koudstaal PJ, Brusselle GG, Sturkenboom MC (2012) Tiotropium Handihaler and the risk of cardio- or cerebrovascular events and mortality in patients with COPD. Pulm Pharmacol Ther 25(1):19\u201326. https:\/\/doi.org\/10.1016\/j.pupt.2011.10.004","journal-title":"Pulm Pharmacol Ther"},{"issue":"5","key":"677_CR13","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","volume":"43","author":"O Caster","year":"2020","unstructured":"Caster O, Aoki Y, Gattepaille LM, Grundmark B (2020) Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations. Drug Saf 43(5):479\u2013487. https:\/\/doi.org\/10.1007\/s40264-020-00911-w","journal-title":"Drug Saf"},{"key":"677_CR14","doi-asserted-by":"publisher","first-page":"f1185","DOI":"10.1136\/bmj.f1185","volume":"346","author":"P Sedgwick","year":"2013","unstructured":"Sedgwick P (2013) Case-control studies: measures of risk. BMJ 346:f1185. https:\/\/doi.org\/10.1136\/bmj.f1185","journal-title":"BMJ"},{"issue":"8","key":"677_CR15","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","volume":"13","author":"KJ Rothman","year":"2004","unstructured":"Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13(8):519\u2013523. https:\/\/doi.org\/10.1002\/pds.1001","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"677_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","volume":"7","author":"Y Zhai","year":"2019","unstructured":"Zhai Y, Ye X, Hu F, Xu J, Guo X, Zhuang Y, He J (2019) Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and drug administration adverse events reporting system. J Immunother Cancer 7(1):286. https:\/\/doi.org\/10.1186\/s40425-019-0754-2","journal-title":"J Immunother Cancer"},{"issue":"1","key":"677_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1378\/chest.08-2367","volume":"137","author":"SS Ogale","year":"2010","unstructured":"Ogale SS, Lee TA, Au DH, Boudreau DM, Sullivan SD (2010) Cardiovascular events associated with ipratropium bromide in COPD. Chest 137(1):13\u201319. https:\/\/doi.org\/10.1378\/chest.08-2367","journal-title":"Chest"},{"key":"677_CR18","unstructured":"ClinCalc.com (2023) Tiotropium. Drug usage statistics, United States, 2013\u20132020. https:\/\/clincalc.com\/DrugStats\/Drugs\/Tiotropium. Accessed 18 Dec 2023"},{"key":"677_CR19","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/COPD.S162646","volume":"13","author":"DP Tashkin","year":"2018","unstructured":"Tashkin DP, Gross NJ (2018) Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 13:1873\u20131888. https:\/\/doi.org\/10.2147\/COPD.S162646","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"1","key":"677_CR20","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.taap.2015.05.012","volume":"287","author":"A Trifilieff","year":"2015","unstructured":"Trifilieff A, Ethell BT, Sykes DA, Watson KJ, Collingwood S, Charlton SJ, Kent TC (2015) Comparing the cardiovascular therapeutic indices of glycopyrronium and tiotropium in an integrated rat pharmacokinetic, pharmacodynamic and safety model. Toxicol Appl Pharmacol 287(1):9\u201316. https:\/\/doi.org\/10.1016\/j.taap.2015.05.012","journal-title":"Toxicol Appl Pharmacol"},{"key":"677_CR21","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/1471-2466-14-4","volume":"14","author":"KR Chapman","year":"2014","unstructured":"Chapman KR, Beeh KM, Beier J, Bateman ED, D\u2019Urzo A, Nutbrown R, Henley M, Chen H, Overend T, D\u2019Andrea P (2014) A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study. BMC Pulm Med 14:4. https:\/\/doi.org\/10.1186\/1471-2466-14-4","journal-title":"BMC Pulm Med"},{"key":"677_CR22","doi-asserted-by":"publisher","first-page":"e18743064211224","DOI":"10.2174\/18743064-v16-e2112240","volume":"16","author":"C Kato","year":"2022","unstructured":"Kato C, Wang D, Nakamura N, Sasajima T, Yoshisue H (2022) Real-world safety and efficacy of glycopyrronium bromide in Japanese patients with COPD: a 52-week post-marketing surveillance. Open Respir Med J 16:e187430642112240. https:\/\/doi.org\/10.2174\/18743064-v16-e2112240","journal-title":"Open Respir Med J"},{"issue":"2","key":"677_CR23","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.pupt.2014.05.005","volume":"28","author":"A Gavald\u00e0","year":"2014","unstructured":"Gavald\u00e0 A, Ramos I, Carcasona C, Calama E, Otal R, Montero JL, Sentellas S, Aparici M, Vilella D, Alberti J, Beleta J, Miralpeix M (2014) The in vitro and in vivo profile of aclidinium bromide in comparison with glycopyrronium bromide. Pulm Pharmacol Ther 28(2):114\u2013121. https:\/\/doi.org\/10.1016\/j.pupt.2014.05.005","journal-title":"Pulm Pharmacol Ther"},{"key":"677_CR24","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2147\/COPD.S363997","volume":"17","author":"C Rebordosa","year":"2022","unstructured":"Rebordosa C, Plana E, Rubino A, Aguado J, Martinez D, Lei A, Daoud S, Saigi-Morgui N, Perez-Gutthann S, Rivero-Ferrer E (2022) Risk assessment of acute myocardial infarction and stroke associated with long-acting muscarinic antagonists, alone or in combination, versus long-acting beta2-agonists. Int J Chron Obstruct Pulmon Dis 17:1715\u20131733. https:\/\/doi.org\/10.2147\/COPD.S363997","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"17","key":"677_CR25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/jama.2019.4973","volume":"321","author":"RA Wise","year":"2019","unstructured":"Wise RA, Chapman KR, Scirica BM, Bhatt DL, Daoud SZ, Zetterstrand S, Reisner C, Gil EG (2019) Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial. JAMA 321(17):1693\u20131701. https:\/\/doi.org\/10.1001\/jama.2019.4973","journal-title":"JAMA"},{"issue":"2","key":"677_CR26","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1124\/jpet.112.202051","volume":"345","author":"M Salmon","year":"2013","unstructured":"Salmon M, Luttmann MA, Foley JJ, Buckley PT, Schmidt DB, Burman M, Webb EF, DeHaas CJ, Kotzer CJ, Barrett VJ, Slack RJ, Sarau HM, Palovich MR, Lain\u00e9 DI, Hay DW, Rumsey WL (2013) Pharmacological characterization of GSK573719 (umeclidinium): a novel, long-acting, inhaled antagonist of the muscarinic cholinergic receptors for treatment of pulmonary diseases. J Pharmacol Exp Ther 345(2):260\u2013270. https:\/\/doi.org\/10.1124\/jpet.112.202051","journal-title":"J Pharmacol Exp Ther"},{"issue":"4\u20135","key":"677_CR27","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1177\/2040622317700822","volume":"8","author":"KS Babu","year":"2017","unstructured":"Babu KS, Morjaria JB (2017) Umeclidinium in chronic obstructive pulmonary disease: latest evidence and place in therapy. Ther Adv Chronic Dis 8(4\u20135):81\u201391. https:\/\/doi.org\/10.1177\/2040622317700822","journal-title":"Ther Adv Chronic Dis"},{"issue":"1","key":"677_CR28","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/1465-9921-15-78","volume":"15","author":"JF Donohue","year":"2014","unstructured":"Donohue JF, Niewoehner D, Brooks J, O\u2019Dell D, Church A (2014) Safety and tolerability of once-daily umeclidinium\/vilanterol 125\/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 15(1):78. https:\/\/doi.org\/10.1186\/1465-9921-15-78","journal-title":"Respir Res"},{"issue":"7","key":"677_CR29","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s40265-017-0731-3","volume":"77","author":"M Cazzola","year":"2017","unstructured":"Cazzola M, Calzetta L, Rinaldi B, Page C, Rosano G, Rogliani P, Matera MG (2017) Management of chronic obstructive pulmonary disease in patients with cardiovascular diseases. Drugs 77(7):721\u2013732. https:\/\/doi.org\/10.1007\/s40265-017-0731-3","journal-title":"Drugs"},{"issue":"10","key":"677_CR30","doi-asserted-by":"publisher","first-page":"e76973","DOI":"10.1371\/journal.pone.0076973","volume":"8","author":"E Posokhova","year":"2013","unstructured":"Posokhova E, Ng D, Opel A, Masuho I, Tinker A, Biesecker LG, Wickman K, Martemyanov KA (2013) Essential role of the m2R-RGS6-IKACh pathway in controlling intrinsic heart rate variability. PLoS ONE 8(10):e76973. https:\/\/doi.org\/10.1371\/journal.pone.0076973","journal-title":"PLoS ONE"},{"issue":"4","key":"677_CR31","doi-asserted-by":"publisher","first-page":"e0193798","DOI":"10.1371\/journal.pone.0193798","volume":"13","author":"K Kulkarni","year":"2018","unstructured":"Kulkarni K, Xie X, Fernandez M, de Velasco E, Anderson A, Martemyanov KA, Wickman K, Tolkacheva EG (2018) The influences of the M2R-GIRK4-RGS6 dependent parasympathetic pathway on electrophysiological properties of the mouse heart. PLoS ONE 13(4):e0193798. https:\/\/doi.org\/10.1371\/journal.pone.0193798","journal-title":"PLoS ONE"},{"issue":"3","key":"677_CR32","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1124\/jpet.116.238345","volume":"360","author":"BR Rorabaugh","year":"2017","unstructured":"Rorabaugh BR, Chakravarti B, Mabe NW, Seeley SL, Bui AD, Yang J, Watts SW, Neubig RR, Fisher RA (2017) Regulator of G protein signaling 6 protects the heart from ischemic injury. J Pharmacol Exp Ther 360(3):409\u2013416. https:\/\/doi.org\/10.1124\/jpet.116.238345","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"677_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.ijcard.2014.09.178","volume":"177","author":"S Patan\u00e8","year":"2014","unstructured":"Patan\u00e8 S (2014) M3 muscarinic acetylcholine receptor in cardiology and oncology. Int J Cardiol 177(2):646\u2013649. https:\/\/doi.org\/10.1016\/j.ijcard.2014.09.178","journal-title":"Int J Cardiol"},{"issue":"3","key":"677_CR34","doi-asserted-by":"publisher","first-page":"372","DOI":"10.2174\/138945013804998963","volume":"14","author":"P Hang","year":"2013","unstructured":"Hang P, Zhao J, Qi J, Wang Y, Wu J, Du Z (2013) Novel insights into the pervasive role of M3 muscarinic receptor in cardiac diseases. Curr Drug Targets 14(3):372\u2013377. https:\/\/doi.org\/10.2174\/138945013804998963","journal-title":"Curr Drug Targets"},{"issue":"1","key":"677_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physiolgenomics.00062.2017","volume":"50","author":"HC Saternos","year":"2018","unstructured":"Saternos HC, Almarghalani DA, Gibson HM, Meqdad MA, Antypas RB, Lingireddy A, AbouAlaiwi WA (2018) Distribution and function of the muscarinic receptor subtypes in the cardiovascular system. Physiol Genom 50(1):1\u20139. https:\/\/doi.org\/10.1152\/physiolgenomics.00062.2017","journal-title":"Physiol Genom"},{"issue":"2","key":"677_CR36","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1124\/jpet.109.151639","volume":"331","author":"A Gavald\u00e0","year":"2009","unstructured":"Gavald\u00e0 A, Miralpeix M, Ramos I, Otal R, Carre\u00f1o C, Vi\u00f1als M, Dom\u00e9nech T, Carcasona C, Reyes B, Vilella D, Gras J, Cortijo J, Morcillo E, Llenas J, Ryder H, Beleta J (2009) Characterization of aclidinium bromide, a novel inhaled muscarinic antagonist, with long duration of action and a favorable pharmacological profile. J Pharmacol Exp Ther 331(2):740\u2013751. https:\/\/doi.org\/10.1124\/jpet.109.151639","journal-title":"J Pharmacol Exp Ther"},{"key":"677_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.2147\/COPD.S36001","volume":"7","author":"R Buhl","year":"2012","unstructured":"Buhl R, Banerji D (2012) Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD. Int J Chron Obstruct Pulmon Dis 7:729\u2013741. https:\/\/doi.org\/10.2147\/COPD.S36001","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"issue":"8","key":"677_CR38","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/S2213-2600(15)00279-9","volume":"3","author":"M Cazzola","year":"2015","unstructured":"Cazzola M, Rogliani P, Matera MG (2015) Cardiovascular disease in patients with COPD. Lancet Respir Med 3(8):593\u2013595. https:\/\/doi.org\/10.1016\/S2213-2600(15)00279-9","journal-title":"Lancet Respir Med"},{"key":"677_CR39","doi-asserted-by":"publisher","first-page":"106461","DOI":"10.1016\/j.rmed.2021.106461","volume":"185","author":"C Kellerer","year":"2021","unstructured":"Kellerer C, Kahnert K, Trudzinski FC, Lutter J, Berschneider K, Speicher T, Watz H, Bals R, Welte T, Vogelmeier CF, J\u00f6rres RA, Alter P (2021) COPD maintenance medication is linked to left atrial size: results from the COSYCONET cohort. Respir Med 185:106461. https:\/\/doi.org\/10.1016\/j.rmed.2021.106461","journal-title":"Respir Med"},{"issue":"5","key":"677_CR40","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/j.chest.2016.02.646","volume":"149","author":"L Calzetta","year":"2016","unstructured":"Calzetta L, Rogliani P, Matera MG, Cazzola M (2016) A systematic review with meta-analysis of dual bronchodilation with LAMA\/LABA for the treatment of stable COPD. Chest 149(5):1181\u20131196. https:\/\/doi.org\/10.1016\/j.chest.2016.02.646","journal-title":"Chest"},{"issue":"8","key":"677_CR41","doi-asserted-by":"publisher","first-page":"3657","DOI":"10.1111\/bcp.15390","volume":"88","author":"M Cazzola","year":"2022","unstructured":"Cazzola M, Page C, Rogliani P, Calzetta L, Matera MG (2022) Dual bronchodilation for the treatment of COPD: from bench to bedside. Br J Clin Pharmacol 88(8):3657\u20133673. https:\/\/doi.org\/10.1111\/bcp.15390","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"677_CR42","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/S2213-2600(18)30054-7","volume":"6","author":"JM Hohlfeld","year":"2018","unstructured":"Hohlfeld JM, Vogel-Claussen J, Biller H, Berliner D, Berschneider K, Tillmann HC, Hiltl S, Bauersachs J, Welte T (2018) Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med 6(5):368\u2013378. https:\/\/doi.org\/10.1016\/S2213-2600(18)30054-7","journal-title":"Lancet Respir Med"},{"issue":"9","key":"677_CR43","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1164\/rccm.201805-0995OC","volume":"199","author":"J Vogel-Claussen","year":"2019","unstructured":"Vogel-Claussen J, Sch\u00f6nfeld CO, Kaireit TF, Voskrebenzev A, Czerner CP, Renne J, Tillmann HC, Berschneider K, Hiltl S, Bauersachs J, Welte T, Hohlfeld JM (2019) Effect of indacaterol\/glycopyrronium on pulmonary perfusion and ventilation in hyperinflated patients with chronic obstructive pulmonary disease (CLAIM): a double-blind, randomized crossover trial. Am J Respir Crit Care Med 199(9):1086\u20131096. https:\/\/doi.org\/10.1164\/rccm.201805-0995OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"677_CR44","doi-asserted-by":"publisher","first-page":"317","DOI":"10.15326\/jcopdf.2022.0386","volume":"10","author":"K Gadhvi","year":"2023","unstructured":"Gadhvi K, Kandeil M, Raveendran D, Choi J, Davies N, Nanchahal S, Wing O, Quint J, Whittaker H (2023) Inhaled corticosteroids and risk of cardiovascular disease in chronic obstructive pulmonary disease: a systematic review and meta-regression. Chronic Obstr Pulm Dis 10(3):317\u2013327. https:\/\/doi.org\/10.15326\/jcopdf.2022.0386","journal-title":"Chronic Obstr Pulm Dis"}],"container-title":["Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00677-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00408-024-00677-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00408-024-00677-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T08:08:20Z","timestamp":1712909300000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00408-024-00677-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,6]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["677"],"URL":"https:\/\/doi.org\/10.1007\/s00408-024-00677-3","relation":{},"ISSN":["0341-2040","1432-1750"],"issn-type":[{"value":"0341-2040","type":"print"},{"value":"1432-1750","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,6]]},"assertion":[{"value":"8 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}